Alpha Cancer Technologies Inc.

ACT is a drug delivery company with an innovative targeted chemotherapy delivery platform for the treatment of cancer. ACT uses recombinant human alpha-fetoprotein to selectively target cancer cells by delivering toxic chemotherapeutic agents exclusively to these cells. This approach offers the benefits of much lower toxicity and greater efficacy compared to conventional chemotherapy.

ACT is a private Canadian company based in Toronto, Ontario.